1-(cyanomethylsulfonylamino)-3-[2-(4-methoxyphenyl)ethyl]-4-(4-methoxyphenyl)-2-imidazolidinone

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑烷类
• 英文名称: 1-(cyanomethylsulfonylamino)-3-[2-(4-methoxyphenyl)ethyl]-4-(4-methoxyphenyl)-2-imidazolidinone
• 英文别名: 1-cyano-N-{4-(4-methoxyphenyl)-3-[2-(4-methoxyphenyl)ethyl]-2-oxoimidazolidin-1-yl}methanesulfonamide；1-(cyanomethylsulfonylamino)-3-[2-(4-methoxyphenyl)ethyl]-4-[4-methoxy-phenyl]-2-imidazolidinone；1-cyano-N-[4-(4-methoxyphenyl)-3-[2-(4-methoxyphenyl)ethyl]-2-oxoimidazolidin-1-yl]methanesulfonamide
• 化学式: C₂₁H₂₄N₄O₅S
• 分子量: 444.511
• InChiKey: FAPNSGCVSUELJK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  31
• 可旋转键数：
  9
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  120
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  1-Amino-3-[2-(4-methoxyphenyl)ethyl]-4-(4-methoxyphenyl)-2-imidazolidinone 、 氰基甲磺酰氯 在 吡啶 作用下， 以 二氯甲烷 为溶剂， 反应 0.75h， 以38%的产率得到1-(cyanomethylsulfonylamino)-3-[2-(4-methoxyphenyl)ethyl]-4-(4-methoxyphenyl)-2-imidazolidinone
  参考文献：
  名称：

  Selective Kv1.5 Blockers: Development of (R)-1-(Methylsulfonylamino)-3-[2-(4-methoxyphenyl)ethyl]-4-(4-methoxyphenyl)-2-imidazolidinone (KVI-020/WYE-160020) as a Potential Treatment for Atrial Arrhythmia

  摘要：

  Atrial fibrillation is the most prevalent form of cardiac arrhythmia. Current treatments extend the atrial effective refractory period by nonselective blockade of cardiac ion channels. An alternative approach selectively targeting the Kv1.5 ion channel offers the opportunity for therapeutic benefit with decreased risk of adverse cardiovascular events. KVI-020 (4g) successfully demonstrated antiarrhythmic efficacy in a canine arrhythmia model, and these findings support its utility as an antiarrhythmic agent.

  DOI：

  10.1021/jm901042m

文献信息

• KV1.5 POTASSIUM CHANNEL INHIBITORS
  申请人：Janusz Michael John

  公开号：US20070299120A1

  公开（公告）日：2007-12-27

  The present invention relates to 1-N-amino-2-imidazolidinones and derivatives thereof which are effective as Kv1.5 potassium channel inhibitors providing atrial-selective antiarrhythmic agents. The present invention further relates to compositions comprising said Kv1.5 potassium channel inhibitors, and to methods for treating cardiac arrhythmia.

  本发明涉及1-N-氨基-2-咪唑啉酮及其衍生物，其作为Kv1.5钾通道抑制剂，提供房颤选择性抗心律失常药物。本发明还涉及含有上述Kv1.5钾通道抑制剂的组合物，以及治疗心律失常的方法。
• US7504517B2
  申请人：——

  公开号：US7504517B2

  公开（公告）日：2009-03-17
• US7803827B2
  申请人：——

  公开号：US7803827B2

  公开（公告）日：2010-09-28
• Selective Kv1.5 Blockers: Development of (<i>R</i>)-1-(Methylsulfonylamino)-3-[2-(4-methoxyphenyl)ethyl]-4-(4-methoxyphenyl)-2-imidazolidinone (KVI-020/WYE-160020) as a Potential Treatment for Atrial Arrhythmia
  作者：Benjamin E. Blass、Andrew Fensome、Eugene Trybulski、Ronald Magolda、Stephen J. Gardell、Kun Liu、Manoj Samuel、Irene Feingold、Christine Huselton、Chris M. Jackson、Laurent Djandjighian、Douglas Ho、James Hennan、John M. Janusz

  DOI：10.1021/jm901042m

  日期：2009.11.12

  Atrial fibrillation is the most prevalent form of cardiac arrhythmia. Current treatments extend the atrial effective refractory period by nonselective blockade of cardiac ion channels. An alternative approach selectively targeting the Kv1.5 ion channel offers the opportunity for therapeutic benefit with decreased risk of adverse cardiovascular events. KVI-020 (4g) successfully demonstrated antiarrhythmic efficacy in a canine arrhythmia model, and these findings support its utility as an antiarrhythmic agent.